Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 401–500 of 910
Improving quality of care in osteoporosis: Opportunities and challenges
Teng, G. G., Warriner, A. H., Curtis, J. R., & Saag, K. G. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0022-9 · Cited by 16
Self-citationSugiyama, T., Suzuki, S., Yoshida, T., Suyama, K., Tanaka, T., Sueishi, M., & Tatsuno, I. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.06.004 · Cited by 16
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Clarke, B. L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79105-4 · Cited by 16
Oswald, A. J., Berg, K. M., Ralston, S. H., & Riches, P. L. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00563-8 · Cited by 16
Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis
Lewiecki, E. M., Kendler, D. L., Davison, K. S., Hanley, D. A., Harris, S. T., McClung, M. R., & Miller, P. D. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.04.044 · Cited by 16
Corticosteroid-Induced Osteoporosis: An Update for Dermatologists
Clarke, B. L. (2012) · American Journal of Clinical Dermatology · doi:10.2165/11594250-000000000-00000 · Cited by 20
Sugiyama, T., Suzuki, S., Yoshida, T., Mayama, T., Hashimoto, N., Suyama, K., Tanaka, T., Sueishi, M., & Tatsuno, I. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4443 · Cited by 15
Mokuda, S., Sawada, N., Matoba, K., Yamada, A., Onishi, M., Okuda, Y., Jouyama, K., Murata, Y., & Takasugi, K. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03347100 · Cited by 15
Azar, A. E. F., Rezapour, A., Alipour, V., Asiabar, A. S., Gray, S., Mobinizadeh, M., Yousefvand, M., & Arabloo, J. (2017) · Medical Journal of the Islamic Republic of Iran · doi:10.14196/mjiri.31.39 · Cited by 15
Kimura, S., Sasase, T., Ohta, T., Sato, E., & Matsushita, M. (2011) · Journal of Veterinary Medical Science · doi:10.1292/jvms.11-0328 · Cited by 15
Premenopausal Osteoporosis: How to Treat?
Martínez‐Morillo, M., Grados, D., & Holgado, S. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.005 · Cited by 22
Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene
Reginster, J., Ferrari, S., & Hadji, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.890927 · Cited by 16
Ljunggren, Ö., Benhamou, C. L., Dekker, J., Kapetanos, G., Kocjan, T., Langdahl, B. L., Napoli, N., Petto, H., Nikolić, T., & Lindh, E. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.907561 · Cited by 16
Recent recommendations on steroid-induced osteoporosis: More targeted, but more complicated
Deal, C. L. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.11094 · Cited by 14
Hirooka, Y., Nozaki, Y., Okuda, S., Sugiyama, M., Kinoshita, K., Funauchi, M., & Matsumura, I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.753185 · Cited by 15
German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis
Leipe, J., Holle, J. U., Weseloh, C., Pfeil, A., & Krüger, K. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01025-z · Cited by 14
Wong, M., Wan, X., Ruff, V. A., Krohn, K., & Taylor, K. A. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1725-8 · Cited by 14
Self-citationde Paula, F. J. A., Black, D. M., & Rosen, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00029-0 · Cited by 20
Glucocorticoid-induced Osteoporosis
Jung, J., & Suh, C. (2017) · Korean Journal of Medicine · doi:10.3904/kjm.2017.92.2.142 · Cited by 15
New insights into the biology of glucocorticoid-induced osteoporosis
Lane, N. E., & Yao, W. (2011) · IBMS BoneKEy · doi:10.1138/20110511 · Cited by 15
Dore, R. K. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s31067 · Cited by 17
Ricciardi, B. F., Paul, J. R., Kim, A., Russell, L., & Lane, J. M. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2113-8 · Cited by 16
Glucocorticoid‐Induced Osteoporosis
Saag, K. G., & Adler, R. A. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch59 · Cited by 16
Self-citationBisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros
Rossini, M., Orsolini, G., Viapiana, O., Adami, S., & Gatti, D. (2015) · Endocrine · doi:10.1007/s12020-014-0506-5 · Cited by 14
Alonso, N., Albagha, O., Azfer, A., Larraz‐Prieto, B., Berg, K. M., Riches, P. L., Ostanek, B., Kocjan, T., Marc, J., Langdahl, B. L., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223618 · Cited by 14
A narrative review of the pharmaceutical management of osteoporosis
Patel, D., Gorrell, C., Norris, J., & Liu, J. (2023) · Annals of Joint · doi:10.21037/aoj-23-2 · Cited by 16
Kao, F., Hsu, Y., Tu, Y., Chen, T., Wang, H., & Lin, J. C.-F. (2023) · Biomedicines · doi:10.3390/biomedicines11102764 · Cited by 13
An insight into the pharmacology of cysteine/methionine containing peptide drugs
Sharma, A., & Singh, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116456 · Cited by 15
Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men
Devogelaer, J., Boutsen, Y., & Manicourt, D. H. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0024-1 · Cited by 14
Nakamura, T., Tsujimoto, M., Hamaya, E., Sowa, H., & Chen, P. (2011) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-011-0313-5 · Cited by 13
Pan Arab Osteoporosis Society Guidelines for Osteoporosis Management
Jassim, N. A., Adib, G., Younis, A. A. R., Gorial, F. I., Maghraoui, A., Al-Suhaili, A. R., Murtaji, A., Otom, A. H., Masri, B. K., Saba, E., et al. (2017) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.28.1.27 · Cited by 16
Abaloparatide: a new anabolic therapy on the horizon
Cosman, F. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.28 · Cited by 13
Hod, T., Riella, L. V., & Chandraker, A. K. (2015) · Clinical Transplantation · doi:10.1111/ctr.12622 · Cited by 13
Songpatanasilp, T., Mumtaz, M. H., Chhabra, H., Yu, M., & Sorsaburu, S. (2014) · Singapore Medical Journal · doi:10.11622/smedj.2014120 · Cited by 15
Perioperative Management of the Rheumatoid Patient
Wolfe, J., Wolfe, J., & Visser, H. J. (2018) · Clinics in Podiatric Medicine and Surgery · doi:10.1016/j.cpm.2018.08.005 · Cited by 16
Shaalan, A. A. M., El‐Sherbiny, M., El-Abaseri, T. B., Shoaeir, M. Z., Abdel-Aziz, T. M., Mohamed, M. I., Zaitone, S. A., & Mohammad, H. M. F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00583 · Cited by 13
Tanaka, I., Tanaka, Y., Soen, S., & Oshima, H. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01171-5 · Cited by 14
Metastatic medullary thyroid carcinoma presenting as ectopic Cushing’s syndrome
Forde, H. E., Farrelly, N. M., Ryan, K., Moran, T., Greally, M., Duffy, A. G., & Byrne, M. M. (2021) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0207 · Cited by 13
WNT7B overexpression rescues bone loss caused by glucocorticoids in mice
Chen, H., Song, F., & Long, F. (2021) · The FASEB Journal · doi:10.1096/fj.202100151rr · Cited by 15
Chen, C., Elsalmawy, A. H., Ish‐Shalom, S., Lim, S., Al-Ali, N. S., Cunha-Borges, J. L., Yang, H., Casas, N., Altan, L., Belaya, Z. E., et al. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00895-4 · Cited by 13
Self-citationBriot, K., & Roux, C. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.11.005 · Cited by 21
Present at the beginning: a personal reminiscence on the history of teriparatide
Marcus, R. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1598-x · Cited by 13
Self-citationPostnov, A., Schutter, T. M. D., Sijbers, J., Karperien, M., & Clerck, N. D. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9301-3 · Cited by 14
Treatment of glucocorticoid-induced osteoporosis
Mazziotti, G., Giustina, A., CANALIS, E. M., & Bilezikian, J. P. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09343222 · Cited by 13
Can adverse effects of glucocorticoid therapy be prevented and treated?
van der Goes, M. C., Strehl, C., Buttgereit, F., Bijlsma, J. W. J., & Jacobs, J. W. G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232390 · Cited by 19
Hurley-Novatny, A. C., Chang, D., Murakami, K., Wang, L., & Li, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398050 · Cited by 21
Effect of Intermittent Systemic Corticosteroid on Bone Metabolism in Bronchial Asthma Patients
Mori, H., 田中, 春., Ohno, Y., Ito, F., Funaguchi, N., Endo, J., La, B. L. B., & Minatoguchi, S. (2009) · Journal of Asthma · doi:10.1080/02770900802492095 · Cited by 12
Systemic glucocorticoids in rheumatology
Saag, K. G., & Buttgereit, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00054-1 · Cited by 12
Self-citationMiyaoka, D., Imanishi, Y., Ohara, M., Hayashi, N., Nagata, Y., Yamada, S., Mori, K., Emoto, M., & Inaba, M. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0295-y · Cited by 12
Fuji, S., Byrne, M. T., Nagler, A., Mohty, M., & Savani, B. N. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01205-6 · Cited by 13
Wang, Y., Li, X., Zhou, S., Li, J., Zhu, Y., Wang, Q., & Zhao, F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7727006 · Cited by 18
Koski, A.-M., Löyttyniemi, E., Väänänen, H., Laine, H. K., NISKANEN, L. K., Nevalainen, P. I., Korpi-Hyövälti, E., & Välimäki, M. J. (2013) · Annals of Medicine · doi:10.3109/07853890.2012.742560 · Cited by 12
A Practical Approach to Osteoporosis Management in the Geriatric Population
Liberman, D., & Cheung, A. M. (2015) · Canadian Geriatrics Journal · doi:10.5770/cgj.18.129 · Cited by 13
Management of osteoporosis with PTH: treatment and prescription patterns in Europe
Hosking, D. J., Alonso, C. G., & Brandi, M. L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802645461 · Cited by 13
Prevention of fractures in patients with osteoporosis
Ferrari, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32167-0 · Cited by 13
Otero, R., Ishizawa, M., Numoto, N., Ikura, T., Ito, N., Tokiwa, H., Mouriño, A., Makishima, M., & Yamada, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00427 · Cited by 12
Lane, N. E., Mohan, G., Yao, W., Shidara, K., Lay, Y.-A. E., Junjing, J., Dubrovsky, A., & Kimmel, D. B. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.10.003 · Cited by 12
Mori, Y., Izumiyama, T., Baba, K., Mori, N., Fujii, H., Ishii, T., & Itoi, E. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01813-4 · Cited by 12
Takahata, M., Shimizu, T., Yamada, S., Yamamoto, T., Hasegawa, T., Fujita, R., Kobayashi, H., Endo, T., Koike, Y., Amizuka, N., et al. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01323-9 · Cited by 12
Badraoui, R., Amri, N., Zammel, N., Chaabane, R., & Rebaï, T. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.04.023 · Cited by 13
Glucocorticoid-induced osteoporosis
Paul, T. V., Cherian, K. E., & Kapoor, N. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_187_17 · Cited by 13
Agarwal, S., Shane, E. J., Lang, T., Shiau, S., Kamanda‐Kosseh, M., Bucovsky, M., Lappe, J. M., Stubby, J., Recker, R. R., Hu, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac232 · Cited by 13
Self-citationCheng, J., ju, S., & Zhang, Z. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06253-9 · Cited by 14
Aimaiti, A., Wufuer, M., Wang, Y.-H., Saiyiti, M., Cui, L., & Yusufu, A. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.04.036 · Cited by 11
Fisher, J., Scott, K., Wei, N., Zhao, J. Z., Cusick, T. E., Tijerina, M., Karanam, B. V., Duong, L. T., & Glantschnig, H. (2012) · Bone · doi:10.1016/j.bone.2012.03.004 · Cited by 11
New strategies for osteoporosis patients previously managed with strontium ranelate
Vestergaard, P. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14552070 · Cited by 12
Clarke, B. L. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79517-2 · Cited by 11
COPD: osteoporosis and sarcopenia
Majid, H., Kanbar-Agha, F., & Sharafkhaneh, A. (2016) · COPD Research and Practice · doi:10.1186/s40749-016-0019-0 · Cited by 14
Efectos adversos de la terapia con glucocorticoides
Gutiérrez-Restrepo, J. (2021) · IATREIA · doi:10.17533/udea.iatreia.96 · Cited by 20
Leipe, J., Holle, J. U., Weseloh, C., Pfeil, A., Krüger, K., & (DGRh), D. K. P. D. D. G. F. R. E. V. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01028-w · Cited by 13
Kidney Transplantation: A Guide to the Care of Kidney Transplant Recipients
McKay, D. B., & Steinberg, S. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1690-7 · Cited by 10
Bush, L. A., & Chew, F. S. (2009) · Radiology Case Reports · doi:10.2484/rcr.v4i1.261 · Cited by 14
Briot, K., Cortet, B., Roux, C., Fardet, L., Abitbol, V., Bacchetta, J., Buchon, D., Debiais, F., Guggenbuhl, P., Laroche, M., et al. (2014) · Revue du Rhumatisme · doi:10.1016/j.rhum.2014.07.009 · Cited by 21
Sugiyama, T., Tatsuno, I., Suzuki, S., Yoshida, T., Tanaka, T., Sueishi, M., & Saitō, Y. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-318 · Cited by 12
Glucocorticoid‐induced osteoporosis
Sambrook, P. N. (2008) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2008.00391.x · Cited by 12
Lane, N. E. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32816a9436 · Cited by 12
Management of postmenopausal osteoporosis
Reid, I. R., & Bolland, M. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag006 · Cited by 15
Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes
Vilaça, T., & Eastell, R. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00833-3 · Cited by 11
Recommendations for Diagnosis and Management of Osteoporosis in COPD Men
Mazokopakis, E. E., & Starakis, I. (2011) · ISRN Rheumatology · doi:10.5402/2011/901416 · Cited by 10
Osteoimmunology and the Osteoblast
Nanes, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00005-0 · Cited by 9
Silva, B. C. C., Madeira, M., d’Alva, C. B., Maeda, S. S., de Holanda, N. C. P., Ohe, M. N., Szejnfeld, V. L., Zerbini, C. A. F., de Paula, F. J. A., & Bandeira, F. A. F. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000522 · Cited by 16
di Filippo, L., Ulivieri, F. M., Nuti, R., & Giustina, A. (2023) · Endocrine · doi:10.1007/s12020-023-03551-z · Cited by 12
Liang, H. D., Yu, F., Lv, P., Zhao, Z. N., & Tong, Z. H. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3315-2 · Cited by 12
BPCO et métabolisme osseux: une mise à jour clinique
Lehouck, A., Remoortel, H. V., Troosters, T., Decramer, M., & Janssens, W. (2010) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.10.007 · Cited by 14
Seno, T., Yamamoto, A., Kukida, Y., Hirano, A., Kida, T., Nakabayashi, A., Fujioka, K., Nagahara, H., Fujii, W., Murakami, K., et al. (2016) · SpringerPlus · doi:10.1186/s40064-016-2704-5 · Cited by 10
Park, J. W., Hwang, S. R., Seo, D.-H., & Byun, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s110573 · Cited by 10
Glucocorticoid-induced osteoporosis
Adachi, J. D. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0696-x · Cited by 10
Medikamenteninduzierte Osteopathien in der Rheumatologie
Fiehn, C., & Bauhammer, J. (2022) · Zeitschrift für Rheumatologie (Print) · doi:10.1007/s00393-021-01145-6 · Cited by 7
Osteoporosis en individuos jóvenes
Bernal, P. P. (2010) · Reumatología Clínica · doi:10.1016/j.reuma.2009.01.014 · Cited by 16
Misiorowski, W. (2011) · PubMed · Cited by 13
Alshayeb, H. M., Sprague, S. M., & Josephson, M. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_24 · Cited by 10
Glucocorticoid‐Induced Bone Disease
Weinstein, R. S. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch58 · Cited by 13
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update
Shi, X., Chutkan, N. B., Mark, W., & Carlos, M. (2012) · InTech eBooks · doi:10.5772/53978 · Cited by 10
Soen, S., Fujiwara, S., Takayanagi, R., Sato, M., Tsujimoto, M., Yamamoto, T., Enomoto, H., & Krege, J. H. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1074063 · Cited by 9
Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop
Ward, L. M., Kinnett, K., Bonewald, L. F., Adachi, J. D., Bachrach, L. K., Bellido, T., Brotto, M. A. P., Bonewald, L. F., Donovan, J. M., Hoffman, E. P., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.05.012 · Cited by 10
Mel'nichenko, G. A., Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Pigarova, E. A., Toroptsova, N. V., Nikitinskaya, O. A., Farba, L. Y., Tarbaeva, N. V., Chernova, T. O., et al. (2016) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2016328-36 · Cited by 10
Fallahnezhad, S., Amini, A., Hajihossainlou, B., Chien, S., Dadras, S., Rezaei, F., & Bayat, M. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.03.015 · Cited by 9
Thyroid Hormones, Glucocorticoids, Insulin, and Bone
Lakatos, P. L., Szili, B., Bakos, B., Takács, I., Putz, Z., & Istenes, I. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_314 · Cited by 9
Metabolic Bone Disease in the Post-transplant Population
Nel, J. D., & Epstein, S. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.007 · Cited by 9
Alder, K. D., White, A. H. A., Chung, Y., Lee, I., Back, J., Kwon, H., Cahill, S. V., Hao, Z., Li, L., Chen, F., et al. (2020) · JBMR Plus · doi:10.1002/jbm4.10359 · Cited by 10
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.